Mittwoch, 3. März 2021
Navigation öffnen
Anzeige:
CAR T Prelaunch
CAR T Prelaunch
 
JOURNAL ONKOLOGIE – STUDIE

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Rekrutierend

NCT-Nummer:
NCT03731832

Studienbeginn:
September 2018

Letztes Update:
01.06.2020

Wirkstoff:
MLN9708, Pomalidomide 4 MG Oral Capsule, Dexamethasone, Cyclophosphamide

Indikation (Clinical Trials):
Multiple Myeloma, Neoplasms, Plasma Cell

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
GWT-TUD GmbH

Collaborator:
-

Studienleiter

Stefan Knop, Prof.
Principal Investigator
Universitätsklinikum Würzburg / Medizinische Klinik und Poliklinik II

Kontakt

Katja Jersemann, Dr.
Kontakt:
Phone: +49 351 25933
Phone (ext.): 188
E-Mail: katja.jersemann@gwtonline.de
» Kontaktdaten anzeigen

Studienlocations (3 von 11)

Klinikum rechts der Isar der TU München / III. Med. Klinik und Poliklinik
81675 Munich
(Bayern)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Florian Bassermann, Prof. Dr. med.
E-Mail: florian.bassermann@tum.de
» Ansprechpartner anzeigen
phase drei Hämato-Onkologischer Studienkreis am Klinikum Aschaffenburg
63739 Aschaffenburg
(Bayern)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Manfred Welslau, Dr.med.
E-Mail: info@onkologie-ab.de
» Ansprechpartner anzeigen
Sozialstiftung Bamberg / Klinik am Bruderwald, Zentrum für Innere Medizin, Med. Klinik V, Hämatologie und internistische Onkologie
96049 Bamberg
(Bayern)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Ruth Seggewiß-Bernhardt, PD.Dr. med.
E-Mail: ruth.seggewiss-bernhardt@sozialstiftung-bamberg.de
» Ansprechpartner anzeigen
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main
60590 Frankfurt am main
(Hessen)
GermanyNoch nicht rekrutierend» Google-Maps
Ansprechpartner:
Ivana von Metzler, Dr. med.
E-Mail: ivana.metzler@kgu.de
» Ansprechpartner anzeigen
Universitätsklinikum Jena / Klinik für Innere Medizin II, Abteilung für Hämatologie und internistische Onkologie
07747 Jena
(Thüringen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Marie von Lilienfeld-Toal, Prof. Dr. med.
E-Mail: marie.von_lilienfeld-toal@med.uni-jena.de
» Ansprechpartner anzeigen
Universitätsklinikum Magdeburg A.Ö.R / Klinik für Hämatologie und Onkologie
39120 Magdeburg
(Sachsen-Anhalt)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Denise Wolleschak, Dr. med.
E-Mail: denise.wolleschak@med.ovgu.de
» Ansprechpartner anzeigen
Kliniken Ostalb Stauferklinikum Schwäbisch Gmünd
73557 Mutlangen
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Holger Hebart, Prof. Dr. med.
E-Mail: holger.hebart@kliniken-ostalb.de
» Ansprechpartner anzeigen
Universitätsklinikum Münster / Medizinische Klinik A
48149 Münster
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Julia Reusch, Dr. med.
E-Mail: julia.reusch@ukmuenster.de
» Ansprechpartner anzeigen
Universitätsklinikum Ulm / Klinik für Innere Medizin III
89081 Ulm
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Miriam Kull, Dr. med.
E-Mail: miriam.kull@uniklinik-ulm.de
» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Detailed Description:

The study is designed as an open-label, non-randomized, multicenter study to investigate the clinical activity of pomalidomide administered once daily in combination with oral ixazomib and dexamethasone (PId) until disease progression according to IMWG criteria.

Patients with clinical relapse (any one of the following: deterioration of renal function, hypercalcemia, newly developing osteolytic lesions and/or soft tissue plasmacytomas) will go off study and receive further treatment according to their treating physician. Patients with isolated biochemical relapse with an increase of serum M-protein of ≥ 25% (absolute increase in serum must be ≥ 5 g/L) and/or urine M-protein (absolute increase in urine must be ≥ 200 mg/24h) or in the difference between involved and uninvolved FLC levels (provided, the absolute increase is > 100 mg/L) without further signs or symptoms will proceed to the intensification phase (PICd).

The intensification phase (PICd) will last until further disease progression. In case of significant haematological and non-haematological toxicities, dose adjustments and/or interruption of the study drugs may be necessary.

Response assessments will be performed every four weeks by evaluation of serum and 24 hour urine specimens. "Progressive disease" (PD) will require a consecutive confirmatory measurement.

Ein-/Ausschlusskriterien

Inclusion criteria:

- Male or female patients ≥ 18 years of age at the time of signing the informed consent form

- Patients capable to understand the purposes and risks of the study, who are willing and able to participate in the study and from whom written and dated informed consent to participate in the study has been obtained prior to any study related assessments/ procedures being conducted

- Patients with relapsed or refractory, histologically confirmed multiple myeloma

- Patients must have received at least two but not more than four prior anti-myeloma regimens including lenalidomide and bortezomib and have demonstrated disease progression on the last therapy

- Prior treatments must have included both lenalidomide and bortezomib: at least two consecutive cycles of lenalidomide and bortezomib (alone or in combination) and adequate prior alkylator exposure. This is either as part of a stem cell transplant or at least 6 consecutive cycles of an alkylator-based therapy.

- Patients must have failed bortezomib and lenalidomide therapy: progression within 60 days; PR or better with progression within 6 month and/or bortezomib intolerant after ≥ 2 cycles and achieving ≤ MR

- Relapsed from or refractory to at least one regimen (induction, autologous stem cell transplantation (or allogenic stem cell transplantation) and consolidation/maintenance are considered one "regimen")

- Measurable levels of serum and/or urine M-protein: serum M-protein ≥ 5 g/L and/or urine M-protein ≥ 200 mg/24h or serum free light chain (sFLC) concentration of > 100 mg/L of the involved FLC, provided sFLC ratio is abnormal (sFLC K/λ ratio (< 0.26 or > 1.65)

- Life expectancy ≥ 3 months

- ECOG performance status of 0, 1, or 2

- Patients must be able to adhere to the study visit schedule and other protocol requirements

- All women and men must acknowledge to have understood the hazards and necessary precautions associated with the use of pomalidomide and ixazomib

- All subjects must agree in writing to strictly adhere to the Pomalidomide Pregnancy Prevention Plan as given in Appendix C

- Females of childbearing potential (FCBP) must:

- Understand the potential teratogenic risk to the unborn child

- Agree to utilize two reliable forms of contraception simultaneously without interruption for at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for at least 90 days after study treatment discontinuation

- Be capable of complying with effective contraceptive measures

- Be informed and understand the potential consequences of pregnancy and the need to notify her study doctor immediately if there is a risk of pregnancy

- Understand the need to commence the study treatment as soon as study drug is dispensed following a negative pregnancy test

- Understand the need and accept to undergo pregnancy testing based on the frequency outlined in this protocol

- Females must agree to abstain from breastfeeding during study participation and for at least 28 days after study drug discontinuation

- Males must agree to use a latex condom during any sexual contact with FCBP while participating in the study and for 90 days following discontinuation from this study, even if he has undergone a successful vasectomy

- Males must also agree to refrain from donating semen or sperm while on the study drugs and for 90 days after discontinuation from this study treatment

- Subjects must agree to refrain from donating blood while on study therapy and for 28 days after discontinuation from this study treatment

- Subjects must agree not to share medication

- Patients must meet the following clinical laboratory criteria:

- Absolute neutrophil count (ANC) 1 x 109/L

- Platelet count 75 x 109/L for patients in whom < 50% of bone marrow nucleated cells are plasma cells

- Platelet count ≥ 30 x 109/L for patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells. (Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment)

- Total bilirubin 1.5 the upper limit of the normal range (ULN)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 ULN

- Calculated creatinine clearance 30 mL/min

Exclusion criteria:

- Concomitant cancer chemo- or radiotherapy (except for local radiation therapy for preexisting lytic lesions)

- Treatment with any investigational product within 60 days prior to first administration of pomalidomide and ixazomib

- Patients eligible for autologous and / or allogeneic stem cell transplantation

- Abnormal/inadequate organ or bone marrow function as defined below (any single parameter to fulfill condition): ANC < 1 x 109/L

- Hemoglobin < 8.0 g/dL (prior RBC transfusion or recombinant human erythropoietin use is permitted)

- Platelet count < 75 x 109/L for patients in whom < 50% of bone marrow nucleated cells are plasma cells

- Platelet count < 30 x 109/L for patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells

- Estimated GFR (MDRD) < 45 ml/min

- AST/ALT > 3 x upper limit of normal (ULN)

- Serum (total) bilirubin > 1.5 x ULN

- Corrected serum calcium > 14 mg/dL (> 3.5 mmol/L); or free ionized calcium > 6.5 mg/dL (> 1.6 mmol/L)

- Serum creatinine > 1.5 x ULN

- Prior pomalidomide based therapy

- Prior ixazomib based therapy

- Baseline peripheral neuropathy > Grade 1 on clinical examination within 14 days before enrollment

- Active HIV, hepatitis B (including patients who are tested Anti-HBc-positive and / or HBsAg-positive) or hepatitis C infection after serologic testing

- Any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the study as judged by the investigator

- Known hypersensitivity to pomalidomide and its analogues in general and/or to ixazomib and its analogues or to any other component of study drugs

- Prior malignancy excluding adequately treated with curative intent basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer without any evidence of residual disease or requiring anti-cancer treatment < 2 years prior to initiating study treatment

- Patients with congestive heart failure NYHA Class III and IV, cardiac arrhythmias (except atrioventricular block type I and II, atrial fibrillation/flutter, bundle brunch block) or other signs and symptoms of relevant cardiovascular disease

- Pregnant women, nursing mothers, lactating women, and women of childbearing potential as well as male subjects who are unwilling to adhere to the guidelines of the treatment-specific pregnancy prevention program

- Unwilling or unable to follow protocol requirements

- Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before randomization in the study

- Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of the study drugs including difficulty swallowing

Studien-Rationale

Primary outcome:

1. Overall Response rate (PId) according to the IMWG criteria. (Time Frame - 1 year throughout study completion):
Overall response rate at PId



Secondary outcome:

1. Disease control rate (Time Frame - 1 year throughout study completion):
Disease control rate in patients receiving PId (at least SD)

2. Overall response rate (Time Frame - 1 year throughout study completion):
Overall response rate (PR or better) for patients intensified with PICd

3. Disease control rate in patients intensified with PICd (at least SD) (Time Frame - 1 year throughout study completion):
Disease control rate in patients intensified with PICd (at least SD)

4. Progression-free survival (PFS) (Time Frame - 1 year throughout study completion):
Progression-free survival (PFS) for patients receiving PId and for patients receiving PICd

5. Overall survival (OS) (Time Frame - 1 year throughout study completion):
Overall survival (OS)

6. Subsequent anti-myeloma regimens (including best response) (Time Frame - 1 year throughout study completion):
Best response during induction by PId

Studien-Arme

  • Experimental: PId
    Treatment of eligible patients with combination of Pomalidomide, Ixazomib, Dexamethasone for all patients until disease progression.
  • Experimental: PICd
    Treatment of patients showing an isolated biochemical relapse at disease progression with combination of Pomalidomide, Ixazomib, Dexamethasone plus Cyclophosphamide.

Geprüfte Regime

  • MLN9708 (Ixazomib 4.0 mg):
    Study drug will be given as a single, oral dose of 4.0 mg weekly (day 1, 8 and 15) for 3 weeks, followed by 1 week without study drug in a 28-day cycle
  • Pomalidomide 4 MG Oral Capsule:
    Study drug will be given as an oral dose of 4.0 mg on day 1 until day 21, followed by 1 week without study drug in a 28-day cycle.
  • Dexamethasone:
    Dexamethasone will be administered as a single, oral dose of 40 mg/day weekly on day 1, 8, 15 and 22 in patients from 18 to 74 years old. For patients ≥ 75 years old dose has to be reduced to 20 mg/day with the same treatment schedule.
  • Cyclophosphamide:
    Cyclophosphamide will be administered once daily as an oral dose of 50 mg on cycle days 1 to 21, followed by one week without drug in a 28-day cycle.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

Die P4-Medizin – Krebstherapie der Zukunft?

Die P4-Medizin – Krebstherapie der Zukunft?
© Fotolia / psdesign1

Die Versorgung von krebskranken Menschen befindet sich in einem grundlegenden Wandel. Die Entwicklung neuer diagnostischer Methoden und individueller Therapien verändert die onkologische Medizin, wie wir sie bisher kennen. Das jüngst gewonnene Wissen über den Krebs und seine molekularbiologische Vielfalt verlangt nach neuen Antworten. In dem vom amerikanischen Biomediziner Leroy Hood geprägten Konzept der P4-Medizin wird die mögliche Krebstherapie der Zukunft...

Krebstherapie-Nebenwirkungen wirksam bekämpfen, Patienten unterstützen – Bundesweit gültige Leitlinie verabschiedet

Krebstherapie-Nebenwirkungen wirksam bekämpfen, Patienten unterstützen – Bundesweit gültige Leitlinie verabschiedet
© vitanovski / Fotolia.com

Etwa eine halbe Millionen Menschen erkranken jedes Jahr in Deutschland an Krebs. Für viele ist die Behandlung mit erheblichen Nebenwirkungen verbunden, die die Lebensqualität der Patienten deutlich beeinträchtigen. Doch längst gibt es wirksame Therapien, um Nebenwirkungen wie Übelkeit und Erbrechen besser in den Griff zu bekommen. Die so genannten unterstützenden oder Supportiven Therapien haben in den vergangenen Jahren eine enorme Entwicklung genommen.